Lindsey focuses her practice on public and private mergers and acquisitions, including cross-border transactions, joint ventures, earn-outs and other complex transactions, representing strategic and financial buyers as well as sellers. She has represented clients across a variety of industries, including life sciences, technology, healthcare, diagnostics and financial services.
Propella Therapeutics Enters Merger Agreement With Astellas Pharma
November 16, 2023
Cooley advised Propella Therapeutics, a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs, on its merger agreement with Astellas Pharma in which Astellas will acquire Propella through a US subsidiary.
Travere Sells Bile Acid Product Portfolio to Mirum
July 18, 2023
Cooley advised Travere Therapeutics, a biopharmaceutical company, on its definitive agreement to sell its bile acid product portfolio to Mirum Pharmaceuticals.
CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion
January 10, 2023
Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.
Cooley advised Tmunity Therapeutics, a clinical-stage biotechnology company, on its agreement to sell to Kite, a global biopharmaceutical company. Partners Mark Weeks, Ben Beerle and Marya Postner led the Cooley team.